| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.0066 | 0.9 |